Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

被引：63
作者：
Tüzün, E
Meriggioli, MN
Rowin, J
Yang, H
Christadoss, P
机构：
[1] Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
[2] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60612 USA
来源：
JOURNAL OF AUTOIMMUNITY | 2005年 / 24卷 / 03期
关键词：
autoimmunity; etanercept; interferon-gamma; interleukin-6; myasthenia gravis;
D O I：
10.1016/j.jaut.2005.01.013
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor: Fc) in a prospective pilot trial. While the plasma anti -acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune coniplexes, IL-10 and IFN-gamma. There was a direct correlation between plasma IL-6, TNF-alpha and IFN-gamma levels and the post-treatment clinical scores of patients. Moreover, patients with lower pretreatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：261 / 268
页数：8
相关论文
共 27 条
[1]   Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia gravis in mice [J].
Balasa, B ;
Deng, CS ;
Lee, J ;
Bradley, LM ;
Dalton, DK ;
Christadoss, P ;
Sarvetnick, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (03) :385-391
[2]   Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein [J].
Christadoss, P ;
Goluszko, E .
JOURNAL OF NEUROIMMUNOLOGY, 2002, 122 (1-2) :186-190
[3]   New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate [J].
Davis, JC ;
Huang, F ;
Maksymowych, W .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (03) :481-+
[4]   Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production [J].
Deng, CS ;
Goluszko, E ;
Tüzün, E ;
Yang, H ;
Christadoss, P .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :1077-1083
[5]   Etanercept: An overview [J].
Goffe, B ;
Cather, JC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :S105-S111
[6]   Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis [J].
Goldenberg, MM .
CLINICAL THERAPEUTICS, 1999, 21 (01) :75-87
[7]   Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis [J].
Goluszko, E ;
Deng, CS ;
Poussin, MA ;
Christadoss, P .
JOURNAL OF NEUROIMMUNOLOGY, 2002, 122 (1-2) :85-93
[8]   Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis [J].
Goluszko, E ;
Hjelmström, P ;
Deng, CS ;
Poussin, MA ;
Ruddle, NH ;
Christadoss, P .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 113 (01) :109-118
[9]   Polymorphism in tumor necrosis factor genes associated with myasthenia gravis [J].
Hjelmstrom, P ;
Peacock, CS ;
Giscombe, R ;
Pirskanen, R ;
Lefvert, AK ;
Blackwell, JM ;
Sanjeevi, CB .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 88 (1-2) :137-143
[10]  
Huang DR, 2001, EUR J IMMUNOL, V31, P225, DOI 10.1002/1521-4141(200101)31:1<225::AID-IMMU225>3.0.CO
123